Phase I / II Clinical Trial of GAIA-102 for advanced and relapse NSCLC
Not Applicable
Recruiting
- Conditions
- advanced and relapse NSCLC
- Registration Number
- JPRN-UMIN000046974
- Lead Sponsor
- GAIA BioMedicine Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients with symptomatological cranial nerve system metastasis. If treatment for cranial nerve system metastasis has already been performed and the neurologically recovered state has been maintained for 2 weeks or more before registration, registration is possible. (2) Patients diagnosed with cancerous meningitis (3) Patients who received allogeneic hematopoietic stem cell transplantation (4) Patients with active autoimmune disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method [Phase I part] - Presence or absence of DLT expression - Frequency and severity of adverse events [Phase II part] - Objective Response Rate
- Secondary Outcome Measures
Name Time Method